VERTEX PHARMACEUTICALS INC / MA Royalty Revenue (Deprecated 2018-01-31)
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Royalty Revenue (Deprecated 2018-01-31) of $1.36 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-04-27.
Discontinued › Income Statement › Other Income
us-gaap:RoyaltyRevenue · last filed 2018-04-27
- VERTEX PHARMACEUTICALS INC / MA royalty revenue (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $1.36M, a 12.57% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA royalty revenue (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $1.34M, a 65.40% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA royalty revenue (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $2.23M, a 41.83% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA royalty revenue (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $2.86M, a 45.83% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA royalty revenue (deprecated 2018-01-31) for fiscal 2017 was $7.99M, a 51.88% decline from fiscal 2016.
- VERTEX PHARMACEUTICALS INC / MA royalty revenue (deprecated 2018-01-31) for fiscal 2016 was $16.60M, a 30.71% decline from fiscal 2015.
- VERTEX PHARMACEUTICALS INC / MA royalty revenue (deprecated 2018-01-31) for fiscal 2015 was $23.96M, a 41.45% decline from fiscal 2014.
- VERTEX PHARMACEUTICALS INC / MA royalty revenue (deprecated 2018-01-31) for fiscal 2014 was $40.92M, a 73.87% decline from fiscal 2013.
| Period end | Royalty Revenue (Deprecated 2018-01-31) 3 month | Royalty Revenue (Deprecated 2018-01-31) 6 month | Royalty Revenue (Deprecated 2018-01-31) 9 month | Royalty Revenue (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-03-31 | $1.36M 10-Q · filed 2018-04-27 | $2.70M derived: sum of 2 quarters · filed 2018-04-27 | $4.93M derived: sum of 3 quarters · filed 2018-04-27 | $7.79M derived: sum of 4 quarters · filed 2018-04-27 |
| 2017-12-31 | $1.34M 10-K · filed 2018-02-15 | $3.58M derived: sum of 2 quarters · filed 2018-02-15 | $6.44M derived: sum of 3 quarters · filed 2018-02-15 | $7.99M 10-K · filed 2018-02-15 |
| 2017-09-30 | $2.23M 10-K · filed 2018-02-15 | $5.09M derived: sum of 2 quarters · filed 2018-02-15 | $6.64M 10-Q · filed 2017-10-30 | $10.53M derived: sum of 4 quarters · filed 2018-04-27 |
| 2017-06-30 | $2.86M 10-K · filed 2018-02-15 | $4.41M 10-Q · filed 2017-07-28 | $8.30M derived: sum of 3 quarters · filed 2018-04-27 | $12.13M derived: sum of 4 quarters · filed 2018-04-27 |
| 2017-03-31 | $1.55M 10-Q · filed 2018-04-27 | $5.44M derived: sum of 2 quarters · filed 2018-04-27 | $9.27M derived: sum of 3 quarters · filed 2018-04-27 | $14.55M derived: sum of 4 quarters · filed 2018-04-27 |
| 2016-12-31 | $3.89M 10-K · filed 2018-02-15 | $7.72M derived: sum of 2 quarters · filed 2018-02-15 | $13.00M derived: sum of 3 quarters · filed 2018-02-15 | $16.60M 10-K · filed 2018-02-15 |
| 2016-09-30 | $3.83M 10-K · filed 2018-02-15 | $9.12M derived: sum of 2 quarters · filed 2018-02-15 | $12.71M 10-Q · filed 2017-10-30 | $19.04M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-06-30 | $5.28M 10-K · filed 2018-02-15 | $8.88M 10-Q · filed 2017-07-28 | $15.21M derived: sum of 3 quarters · filed 2018-02-15 | $20.97M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-03-31 | $3.60M 10-K · filed 2018-02-15 | $9.93M derived: sum of 2 quarters · filed 2018-02-15 | $15.69M derived: sum of 3 quarters · filed 2018-02-15 | $20.76M derived: sum of 4 quarters · filed 2018-02-15 |
| 2015-12-31 | $6.33M 10-K · filed 2017-02-23 | $12.09M derived: sum of 2 quarters · filed 2017-02-23 | $17.17M derived: sum of 3 quarters · filed 2017-02-23 | $23.96M 10-K · filed 2018-02-15 |
| 2015-09-30 | $5.76M 10-K · filed 2017-02-23 | $10.84M derived: sum of 2 quarters · filed 2017-02-23 | $17.63M 10-Q · filed 2016-10-31 | $26.41M derived: sum of 4 quarters · filed 2017-02-23 |
| 2015-06-30 | $5.08M 10-K · filed 2017-02-23 | $11.87M 10-Q · filed 2016-08-01 | $20.65M derived: sum of 3 quarters · filed 2017-02-23 | $29.04M derived: sum of 4 quarters · filed 2017-02-23 |
| 2015-03-31 | $6.79M 10-K · filed 2017-02-23 | $15.58M derived: sum of 2 quarters · filed 2017-02-23 | $23.96M derived: sum of 3 quarters · filed 2017-02-23 | $36.98M derived: sum of 4 quarters · filed 2017-02-23 |
| 2014-12-31 | $8.79M 10-K · filed 2016-02-16 | $17.17M derived: sum of 2 quarters · filed 2016-02-16 | $30.19M derived: sum of 3 quarters · filed 2016-02-16 | $40.92M 10-K · filed 2017-02-23 |
| 2014-09-30 | $8.39M 10-K · filed 2016-02-16 | $21.40M derived: sum of 2 quarters · filed 2016-02-16 | $32.13M 10-Q · filed 2015-10-30 | $69.02M derived: sum of 4 quarters · filed 2016-02-16 |
| 2014-06-30 | $13.02M 10-K · filed 2016-02-16 | $23.75M 10-Q · filed 2015-08-04 | $60.63M derived: sum of 3 quarters · filed 2016-02-16 | $87.65M derived: sum of 4 quarters · filed 2016-02-16 |
| 2014-03-31 | $10.73M 10-K · filed 2016-02-16 | $47.62M derived: sum of 2 quarters · filed 2016-02-16 | $74.63M derived: sum of 3 quarters · filed 2016-02-16 | $123.75M derived: sum of 4 quarters · filed 2016-02-16 |
| 2013-12-31 | $36.89M 10-K · filed 2015-02-13 | $63.90M derived: sum of 2 quarters · filed 2015-02-13 | $113.02M derived: sum of 3 quarters · filed 2015-02-13 | $156.59M 10-K · filed 2016-02-16 |
| 2013-09-30 | $27.01M 10-K · filed 2015-02-13 | $76.13M derived: sum of 2 quarters · filed 2015-02-13 | $119.70M 10-Q · filed 2014-11-06 | $163.16M derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-06-30 | $49.12M 10-K · filed 2015-02-13 | $92.69M 10-Q · filed 2014-07-31 | $136.14M derived: sum of 3 quarters · filed 2015-02-13 | $161.73M derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-03-31 | $43.57M 10-K · filed 2015-02-13 | $87.02M derived: sum of 2 quarters · filed 2015-02-13 | $112.61M derived: sum of 3 quarters · filed 2015-02-13 | $146.09M derived: sum of 4 quarters · filed 2015-02-13 |
| 2012-12-31 | $43.45M 10-K · filed 2014-02-11 | $69.04M derived: sum of 2 quarters · filed 2014-02-11 | $102.52M derived: sum of 3 quarters · filed 2014-02-11 | $141.50M 10-K · filed 2015-02-13 |
| 2012-09-30 | $25.59M 10-K · filed 2014-02-11 | $59.07M derived: sum of 2 quarters · filed 2014-02-11 | $98.05M 10-Q · filed 2013-11-07 | $123.45M derived: sum of 4 quarters · filed 2014-02-11 |
| 2012-06-30 | $33.48M 10-K · filed 2014-02-11 | $72.46M 10-Q · filed 2013-08-02 | $97.87M derived: sum of 3 quarters · filed 2014-02-11 | $106.41M derived: sum of 4 quarters · filed 2014-02-11 |
| 2012-03-31 | $38.98M 10-K · filed 2014-02-11 | $64.39M derived: sum of 2 quarters · filed 2014-02-11 | $72.92M derived: sum of 3 quarters · filed 2014-02-11 | $82.94M derived: sum of 4 quarters · filed 2014-02-11 |
| 2011-12-31 | $25.41M 10-K · filed 2013-03-01 | $33.94M derived: sum of 2 quarters · filed 2013-03-01 | $43.95M derived: sum of 3 quarters · filed 2013-03-01 | $50.02M 10-K · filed 2014-02-11 |
| 2011-09-30 | $8.54M 10-K · filed 2013-03-01 | $18.55M derived: sum of 2 quarters · filed 2013-03-01 | $24.61M 10-Q · filed 2012-11-06 | $33.01M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-06-30 | $10.01M 10-K · filed 2013-03-01 | $16.07M 10-Q · filed 2012-08-08 | $24.47M derived: sum of 3 quarters · filed 2013-03-01 | $32.65M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-03-31 | $6.06M 10-K · filed 2013-03-01 | $14.46M derived: sum of 2 quarters · filed 2013-03-01 | $22.64M derived: sum of 3 quarters · filed 2013-03-01 | $29.90M derived: sum of 4 quarters · filed 2013-03-01 |
| 2010-12-31 | $8.40M 10-K · filed 2012-02-22 | $16.57M derived: sum of 2 quarters · filed 2012-02-22 | $23.84M derived: sum of 3 quarters · filed 2012-02-22 | $30.24M 10-K · filed 2013-03-01 |
| 2010-09-30 | $8.17M 10-K · filed 2012-02-22 | $15.44M derived: sum of 2 quarters · filed 2012-02-22 | $21.84M 10-Q · filed 2011-11-03 | $30.27M derived: sum of 4 quarters · filed 2012-02-22 |
| 2010-06-30 | $7.26M 10-K · filed 2012-02-22 | $13.67M 10-Q · filed 2011-08-09 | $22.10M derived: sum of 3 quarters · filed 2012-02-22 | $29.93M derived: sum of 4 quarters · filed 2012-02-22 |
| 2010-03-31 | $6.41M 10-K · filed 2012-02-22 | $14.84M derived: sum of 2 quarters · filed 2012-02-22 | $22.67M derived: sum of 3 quarters · filed 2012-02-22 | $28.59M derived: sum of 4 quarters · filed 2012-02-22 |
| 2009-12-31 | $8.43M 10-K · filed 2011-02-17 | $16.26M derived: sum of 2 quarters · filed 2011-02-17 | $22.18M derived: sum of 3 quarters · filed 2011-02-17 | $28.32M 10-K · filed 2012-02-22 |
| 2009-09-30 | $7.83M 10-K · filed 2011-02-17 | $13.75M derived: sum of 2 quarters · filed 2011-02-17 | $19.89M 10-Q · filed 2010-10-28 | |
| 2009-06-30 | $5.92M 10-K · filed 2011-02-17 | $12.06M 10-Q · filed 2010-08-03 | ||
| 2009-03-31 | $6.14M 10-K · filed 2011-02-17 | |||
| 2008-12-31 | $37.48M 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |